A small protein involved in neurodegeneration leading to Parkinson's disease also drives a type of skin cancer known as ...

A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 ... which cleared phase 1, but was side-lined for strategic reasons, and also abandoned an alpha-syn gene therapy ...

Results Plasma levels of α-synuclein were significantly higher in patients with PD compared with controls (median: 1.56 pg/mL, 95% CI 1.02 to 1.98 pg/mL vs 0.02 pg/mL, 95% CI 0.01 to 0.03 pg/mL; ...

Listening to the news can feel like a journey. But 1A guides you beyond the headlines – and cuts through the noise. Let's get to the heart of the story, together – on 1A.

All times are UK and subject to change. BBC is not responsible for any changes. Copyright © 2025 BBC. The BBC is not responsible for the content of external sites ...